Marja-Riitta Taskinen

Surgery · 2001–2021

A researcher in the Science corpus: 22 papers; trusts 5 researchers and is trusted by 15 researchers here, as inferred from the citation graph.

Subfields

Surgery — 401 citations into it; #78 of 1,106 by trust here, #35 by citations
Endocrinology, Diabetes and Metabolism — 270 citations into it; #43 of 623 by trust here, #29 by citations
Cancer Research — 81 citations into it; #328 of 1,780 by trust here, #905 by citations
Physiology — 62 citations into it
Genetics — 58 citations into it
Radiology, Nuclear Medicine and Imaging — 42 citations into it

Whom Marja-Riitta Taskinen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

Who trusts Marja-Riitta Taskinen overall

Papers from Marja-Riitta Taskinen's perspective

Ordered by how strongly the researchers Marja-Riitta Taskinen trusts endorse each paper. Same corpus, a different order for every researcher.

Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. (Molecules and Cells)
Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. (Journal of Clinical Endocrinology and Metabolism)
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase (Nature Medicine)
Diabetic dyslipidaemia: from basic research to clinical practice* (Diabetologia)
Global and societal implications of the diabetes epidemic (Nature)
ATVB In Focus Metabolic Syndrome and Atherosclerosis
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (European Heart Journal)
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. (Circulation Research)
Role of oxidative modifications in atherosclerosis. (Physiological Reviews)
Metabolic origins and clinical significance of LDL heterogeneity DOI 10.1194/jlr.R200004-JLR200 (Journal of Lipid Research)

Their papers

Genome-Wide Association Analysis Identifies Loci for Type 2 Diabetes and Triglyceride Levels (2007) — 2,928 citations
Cardiovascular morbidity and mortality associated with the metabolic syndrome. (2001) — 4,989 citations
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) — 742 citations
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel (2020) — 1,302 citations
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019) — 4,665 citations
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. (2019) — 3,945 citations
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017) — 3,303 citations
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment (2015) — 768 citations
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (2014) — 765 citations
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease (2013) — 2,141 citations
ESC/EAS Guidelines for the Management of Dyslipidaemias (2013) — 2,678 citations
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011) — 1,241 citations
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) — 1,417 citations
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) — 1,187 citations
Lipoprotein(a) as a cardiovascular risk factor: current status (2010) — 1,754 citations
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans (2008) — 1,459 citations
ATVB In Focus Metabolic Syndrome and Atherosclerosis (2008) — 833 citations
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. (2007) — 1,027 citations
Overproduction of large VLDL particles is driven by increased liver fat content in man (2006) — 707 citations
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. (2005) — 3,034 citations